TCIM
JUNO

TIAA CREF Investment Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

TIAA CREF Investment Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-193,183
Closed -$8.83M – 3101
2017
Q4 		$8.83M Sell
193,183
-1,325
-0.7% -$66.1K 0.01% 1210
2017
Q3 		$8.73M Buy
194,508
+6,027
+3% +$205K 0.01% 1232
2017
Q2 		$5.63M Buy
188,481
+15,491
+9% +$382K ﹤0.01% 1514
2017
Q1 		$3.84M Sell
172,990
-7,642
-4% -$164K ﹤0.01% 1754
2016
Q4 		$3.4M Sell
180,632
-5,954
-3% -$146K ﹤0.01% 1874
2016
Q3 		$5.6K Sell
186,586
-136,476
-42% -$4.25M ﹤0.01% 1534
2016
Q2 		$12.4M Buy
323,062
+147,180
+84% +$6.11M 0.01% 946
2016
Q1 		$6.7M Buy
175,882
+7,357
+4% +$256K 0.01% 1305
2015
Q4 		$7.41M Buy
168,525
+94,518
+128% +$4.69M 0.01% 1271
2015
Q3 		$3.01M Buy
74,007
+15,432
+26% +$677K ﹤0.01% 1891
2015
Q2 		$3.12M Buy
58,575
+50,029
+585% +$2.66M ﹤0.01% 2010
2015
Q1 		$518K Sell
8,546
-16,794
-66% -$815K ﹤0.01% 2908
2014
Q4 		$1.32M Buy
+25,340
New +$1.13M ﹤0.01% 2495

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

TIAA CREF Investment Management's JUNO Position: Q1 2018 in Review

TIAA CREF Investment Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 193,183 shares — an estimated $8.83M sold.

TIAA CREF Investment Management first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $12.4M in Q2 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • TIAA CREF Investment Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 193,183 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $8.83M.
  • TIAA CREF Investment Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • TIAA CREF Investment Management's Juno Therapeutics, Inc. position peaked at $12.4M in Q2 2016.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on TIAA CREF Investment Management's 13F filing for Q1 2018, filed 14 May 2018.